Simrat Randhawa
CIK: 0001992260
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Dianthus Therapeutics, Inc. /DE/
Discretionary Trading P&L
Holdings
Transaction History (30 total)
- Sep 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct6.2K shares at avg. $21.77$136K - Sep 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct9.4K shares at avg. $22.07$207K - Sep 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct2.6K shares at avg. $105.19$273K - Sep 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct7.2K shares at avg. $106.25$767K - Sep 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct13.3K shares at avg. $106.74$1.4M - Sep 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct7.5K shares at avg. $17.88$134K - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct6.9K shares at avg. $17.88$124K - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct6.2K shares at avg. $21.77$136K - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct9.4K shares at avg. $22.07$207K - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct5.4K shares at avg. $89.72$487K - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct16.9K shares at avg. $90.72$1.5M - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct4.2K shares at avg. $91.37$380K - Jun 1, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct4K shares at avg. $8.44$34K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct8K shares at avg. $8.44$68K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct5K shares at avg. $17.88$89K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct8.3K shares at avg. $21.77$181K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct12.5K shares at avg. $22.07$276K - Mar 12, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct33.8K shares at avg. $81.48$2.8M - Feb 3, 2026DNTH
Dianthus Therapeutics, Inc. /DE/
Award(A)DirectStock Option (Right to Buy)
150K shares- - Nov 14, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct37.5K shares at avg. $21.77$816K - Nov 14, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct40.3K shares at avg. $17.88$720K - Nov 14, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct31.3K shares at avg. $22.07$690K - Nov 14, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Sale(S)Direct109K shares at avg. $38.14$4.2M - Nov 13, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct3.5K shares at avg. $17.88$63K - Nov 13, 2025DNTH
Dianthus Therapeutics, Inc. /DE/
Exercise(M)Direct84K shares at avg. $8.44$709K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 6,249 | $21.77 | $136,041 | Direct |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 9,375 | $22.07 | $206,906 | Direct |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 2,600 | $105.19 | $273,494 | Direct |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 7,215 | $106.25 | $766,594 | Direct |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 13,309 | $106.74 | $1,420,603 | Direct |
| Sep 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 7,500 | $17.88 | $134,100 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 6,908 | $17.88 | $123,515 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 6,249 | $21.77 | $136,041 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 9,375 | $22.07 | $206,906 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 5,428 | $89.72 | $487,000 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 16,943 | $90.72 | $1,537,069 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 4,159 | $91.37 | $380,008 | Direct |
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 3,998 | $8.44 | $33,743 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 7,998 | $8.44 | $67,503 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 5,000 | $17.88 | $89,400 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 8,332 | $21.77 | $181,388 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 12,500 | $22.07 | $275,875 | Direct |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 33,830 | $81.48 | $2,756,468 | Direct |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | Award(A) Stock Option (Right to Buy) | 150,000 | - | - | Direct |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 37,494 | $21.77 | $816,244 | Direct |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 40,287 | $17.88 | $720,332 | Direct |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 31,250 | $22.07 | $689,688 | Direct |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Sale(S) | 109,031 | $38.14 | $4,158,442 | Direct |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 3,529 | $17.88 | $63,099 | Direct |
| Nov 13, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | Exercise(M) | 83,978 | $8.44 | $708,774 | Direct |
1-25 of 30 transactions
About Randhawa Simrat
Randhawa Simrat (SEC CIK 0001992260) files insider reports with the SEC as EVP, Head of R&D of Dianthus Therapeutics, Inc. /DE/ (DNTH).
Signal8 holds 7 ownership filings by Randhawa Simrat, all Form 4s, filed between Feb 4, 2025 and Sep 3, 2026. Those filings report 30 transactions, from Feb 3, 2025 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Randhawa Simrat's filings is in NEW YORK, NY.
Recent filings by Randhawa Simrat
- Sep 1, 2026: Option exercises of DNTH shares (2 lines, Form 4, code M).
- Sep 1, 2026: Open-market sales of DNTH shares (3 lines, Form 4, code S).
- Sep 1, 2026: Option exercise of DNTH shares (Form 4, code M).
- Jun 1, 2026: Option exercises of DNTH shares (3 lines, Form 4, code M).
- Jun 1, 2026: Open-market sales of DNTH shares (3 lines, Form 4, code S).
Other insiders filing for Dianthus Therapeutics, Inc. /DE/ (DNTH)
- CARR EDWARD, CHIEF ACCOUNTING OFFICER
- Read Simon, Director
- Veness Adam M, SVP, General Counsel and Sec.
- McGeorge Anne, Director
- Garcia Marino, CEO AND PRESIDENT
- Savitz Ryan, EVP, CFO & CBO